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Abstract. 
COVID-19 is an emergent viral infection which rose in December 2019 in a city in the 
Chinese province of Hubei, Wuhan; the viral aetiology of this infection is now known as 
COVID-19 virus, which belongs to the Betacoronavirus genus. This virus produces the 
syndrome of acute respiratory stress that h as been witnessed in other coronaviruses, such 
as that MERS-CoV in Middle East countries or SARS-CoV which was seen in 2002 and 
2003 in China. This virus mediates its entry through its spike (S) proteins interacting with 
ACE2 receptors in lung epithelial cells, and may promote an inflammatory response by 
means of inflammasome NLRP3 activation and unfolded protein response (these are 
possibly consequence of the envelope E protein of COVID-19 virus). Efforts have been 
made worldwide to prevent further spread of the disease, but in March 2020 the WHO 
declared it a pandemic emergency and Mexico started to report its first cases. In this paper 
we attempt to summarize the biological features of the virus and the possible 
pathophysiological mechanisms of its disease, as well as a stochastic model 
characterizing the probability distribution of cases in Mexico by states and the estimated 
number of cases in Mexico through a differential equation model (modified SIR model), 
thus will we be able to characterize the disease and its course in Mexico in order to display 
more preparedness and promote more logical actions by both the policy makers as well 
as the general population.  
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Introduction.  
Coronaviruses are known for causing respiratory (if not gastrointestinal or neurological) 
diseases in both humans and animals, however before 2002 and 2003 outbreaks of severe 
acute respiratory syndrome (SARS) in China, this set of viruses was thought to cause 
mainly affection in animals (Cui, Li, & Shi, 2019), for it has been calculated that annually 
40𝑥109 Gallus gallus domesticus specimens in the world suffer from infectious 
bronchitis coronavirus and that 90% of the infected swine by porcine transmissible 
gastroenteritis coronavirus die (Cavanagh, 2005). After the 2002-2003 outbreak of SARS 
in China, another epidemiologically relevant coronavirus infection rose in Middle East 
countries represented by the Middle East respiratory syndrome coronavirus (MERS-
CoV); finally, by the end of 2019, an increase in pneumonias of unknow origin was 
revealed in Wuhan, a city in the province of Hubei in China, which were later revealed to 
be etiologically related by a novel coronavirus, say 2019-nCoV.  
Biology and pathophysiology of coronaviruses.  
Coronaviruses are members of the Nidovirales order according to the International 
Committee on Taxonomy of Viruses (de Groot, et al., 2018) belonging to the 
Cornidovirineae suborder, being themselves a family of viruses, the Coronaviridae in 
which we may encounter two subfamilies: Letovirinae and Orthocoronavirinae; it is 
within the latter subfamily of viruses that we find the genera: Alphacoronavirus, 
Betacoronavirus, Deltacoronavirus and Gammacoronavirus. SARS-2003-related 
coronavirus is found in the subgenus Sarbecovirus of Betacoronaviruses; while MERS-
CoV is found in the subgenus Merbecovirus of Betacoronaviruses. An alternative 
classification was proposed in which coronaviruses are grouped in tetramers: Group 1 
(TGEV, FCoV, CECoV, PEDV, HCoV-229E), Group 2 (HEV, BCoV, CRCoV, MHV, 
RtCoV, PuCoV, HCoV-OC43), Group 3 (IBV, TCoV, PhCoV) and Group 4 (SARS-
CoV) (Cavanagh, 2005). Coronaviruses are enveloped positive-sense RNA viruses and 
display the largest genome sizes amongst all RNA viruses (from 26.2 to 31.7 kb 
(McBride, van Zyl, & Fielding, 2014). The virions have diameters that range from 80 to 
120 nm, however smallest as 50 nm and largest as 200 nm diameters have been noted. 
From the envelope some proteins project from 15 to 20 nm, these are spike (S) proteins 
and all coronaviruses have genes to code these proteins (S gene) which internalize in the 
virion and are mechanically bound by means of a “foot” like extension of 10 nm long. 
Along with these spike proteins, there exist shorter proteins which protrude the virion 
surface from 5 to 10 nm, these being the hemagglutinin-esterase (HE) proteins (Masters, 
2006). The nucleocapsid protein (CoVN) shows conserved regions: N terminal domain 
(NTD), C-terminal domain (CTD) and an intrinsically disordered central region (RNA-
binding domain); however the name of the domains, all three of them have been shown 
to interact with viral RNA. The NTD has shown a grade of divergence amongst 
coronaviruses both in amino acid content and length, this domain associated with the 3’ 
end of the viral RNA genome by means of Gaussian electrostatic interactions; the NTD 
shows convergence in some structural aspects: secondary structures, such as the beta sheet 
flanked by alpha helices, a basic RNA binding groove, enrichment in aromatic and basic 
residues. The NTD resembles “hand”-like structure: an acidic wrist, a hydrophobic palm 
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and basic fingers. The CTD domain is hydrophobic and promotes homodimerization of 
the nucleoprotein (sometimes, not only homodimerization but also oligomerization). This 
protein promotes the formation of the viral capsid protecting the virus from degradation 
by extracellular agents; the self-association of the N protein has been seen as a target in 
coronavirus infection treatment (McBride, van Zyl, & Fielding, 2014). Within the 
coronavirus genome we may find the polyproteins, which show replicase activity; this 
protein uses the genome as the template for the synthesis producing mRNAs, these are 
then translated into structural proteins and others; the structural proteins transit then hatch 
to the endoplasmic reticulum (ER) transiting then towards the ER-Golgi intermediate 
compartment (ERGIC). The nucleocapsids are formed when the progeny genomes 
interact with the N protein; these newly formed nucleocapsids bud into the ERGIC, 
forming then virions ready to exit the cell (Masters, 2006). Coronaviruses’ spike proteins 
have been shown to interact with cellular receptors for their internalization into the cell, 
such as the human aminopeptidase N protein (ANPEP, membrane alanyl aminopeptidase) 
and the angiotensin-converting enzyme 2 (ACE2) (Masters, 2006).  
CoV proteins.  
Spike (S) protein.  
This protein contains three segments: a large ectodomain (which consists of a subunit S1 
with receptor-binding activity and an S2 subunit with membrane-fusion activity), a 
transmembrane anchor and an intracellular tail. Trimerization of the protein is in order 
when seen at the microscope having S1 subunits in one extracellular extreme and S2 
subunits in the other extreme. Various domains of the spike protein bind to different 
proteins/receptors in the host: S1-N-terminal domain binds to sugars (in 
Alphacoronavirus), to CEACAM1 (in MHV Betacoronavirus), and sugars in BCoV and 
IBV (a Gammacoronavirus). Whereas the S1-C-terminal domain binds to ACE2 (in 
Alphacoronaviruses and SARS-CoV), aminopeptidase N (TGEV-PEDV, PRCV), and 
DPP4 (in MERS-CoV). The S1 subunits display divergence in their sequences across 
genera, however convergence is seen in those of the same genus. The S1 C-terminal 
domain subunit contains itself two subdomains (as it has been seen in that S protein 
corresponding to SARS-CoV) these subdomains are: a core structure and a receptor-
binding motif, this latter subdomain binds to ACE2 by means of a concave outer surface, 
this concavity is formed by a beta-sheet with two ridges (loops). Two virus-binding 
residues in ACE2 have been shown to highly contribute to the binding of the virus by 
promoting a regional hydrophobic environment: Lys31 and Lys353; this specificity can 
tell us about how a couple of mutations in both ACE2 or the S1 subunit in the spike 
protein may promote either resistance (or increased susceptibility) or species tropism in 
regards to the infection. This S1-C-terminal subunit in MERS-CoV binds to DPP4, this 
subunit contains as well, in itself, two subdomains: a core structure and a receptor binding 
motif, however this motif is not concave but flat, and DPP4 forms a homodimer, each 
monomer with a hydrolase domain and a beta-propeller domain (Li, 2016), said structure 
(beta propellers) have been seen in various species, and several classes are known, 
depending on the symmetry axis, for instance, the neuraminidase protein of the influenza 
virus has six four-stranded beta sheets; this beta propeller structure is a highly 
symmetrical structure with four to eight-fold repeats of a four-stranded antiparallel beta-
sheet motif, this beta sheets are arranged around a central tunnel, and a hydrophobic 
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character of the interactions provides the stability (Pons, Gómez, Chinea, & Valencia, 
2003), in the case of DPP4, the viral binding motifs are seen in the other surface of the 
beta propeller domain (Li, 2016). It has been noted that the COVID19 S2 subunit displays 
a high degree of conservation, contrary to the S1 subunit with 40% of identity with other 
SARS-CoVs (Cascella, Rajnik, Dulebohn, & Di Napoli, 2020). The spike protein has 
been considered a member of the class I viral membrane fusion proteins, including those 
from: influenza virus, human immunodeficiency virus and Ebola virus; in which we may 
see: hemagglutinin glycoprotein corresponding to the influenza virus, Env protein in HIV 
(trimer of gp120 and gp41 heterodimers (Wilen, Tilton, & Doms, 2012)), and GP 
(glycoprotein) in Ebola virus (which is a triplet of heterodimers, composed of a receptor 
binding subunit GP1, and a fusion subunit GP2) (Salata, et al., 2019). Analogies can be 
made from the fusion process corresponding to influenza virus and hemagglutinin, for 
which there exist both a prefusion and a postfusion state, in the latter one there exists a 
dramatic conformational change, fusion peptides are exposed and insert into the target 
membrane, there is an energy barrier for such a conformational change which may be 
overcome by means of receptor binding (as seen in HIV fusion), low pH (influenza virus) 
or both (avian leucosis virus); this energy barrier in coronavirus is thought to be worked 
out by means of proteolysis of the spike proteins: proprotein convertases, during virus 
packaging, extracellular proteases, cell surface proteases, lysosomal proteases; low pH 
and receptor binding (as seen in other class I fusion proteins) may as well promote the 
reaction and overcome the energy barrier (Li, 2016).  
Hemagglutinin-esterase (HE) protein.  
This protein is exclusive to those corresponding to the group 2a of coronaviruses (Zeng, 
Langereis, van Vliet, Huizinga, & de Groot, 2008) (mouse hepatitis virus, rat coronavirus, 
human respiratory coronaviruses OC43 (HCoV-OC43), HKU1, canine respiratory CoV, 
porcine hemagglutinating encephalomyelitis virus, equine coronavirus, bovine 
coronavirus and wild-ruminant coronaviruses (Hasoksuz, Vlasova, & Saif, 2008)), 
toroviruses and orthomyxoviruses; this would indicate that RNA recombination and 
genetic transfer may have occurred in the past. In coronaviruses, HE does not possess 
fusion activity and is merely accessory to the spike protein, nevertheless, they do bind to 
sialic acid and have shown to have receptor-destroying activity. The CoV HE has three 
domains: a receptor binding domain, an acetylesterase domain, and a membrane-proximal 
domain (the thrice show equivalence with those of HEF influenza protein) (Zeng, 
Langereis, van Vliet, Huizinga, & de Groot, 2008).  
Envelope (E) protein.  
It is an integral membrane protein of 76 to 109 amino acids with a molecular weight 
ranging from 8.4 to 12 kDa; this protein has a short hydrophylic N-terminus followed by 
a large hydrophobic transmembrane domain, ending with a hydrophilic C-terminus; the 
transmembrane domain contains ≥ 1 alpha-helix which may oligomerize and forms an 
ion-conductive pore. It has been also noted that mutations to the PDZ-binding motif 
(PBM) are endured and may show value in vaccine development. It may have a function 
in virion budding as it interacts with the Golgi apparatus. It has showed interesting protein 
interactions with hosts, such as the one noted with BCLXL (BCL2 like 1), PALS1 
(MPP5), Na/K ATPase alpha1 subunit, stomatin. Because of its interactions with the 
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endoplasmic reticulum, this has been linked to enhancement of the unfolded protein 
response (UPR) during infection; and due to the fact that the envelope protein promotes 
the formation of viroporins, transport of calcium by the E protein promotes 
inflammosome activation (Schoeman & Fielding, 2019).  
Host proteins.  
ACE2.  
This gene encodes the angiotensin I converting enzyme 2, which is a member of the 
angiotensin-converting enzyme family of dipeptidyl carboxypeptidases showing 
homology to human angiotensin I converting enzyme. This enzyme catalyzes the 
cleavage of angiotensin I into angiotensin (1-9) and angiotensin II into angiotensin (1-7); 
it is as well a receptor for the novel COVID19-virus. The gene encoding for this protein 
is found in Xp22.2 and has 21 exons. This protein is expressed in the following tissues: 
colon, duodenum, fat, gall bladder, heart, kidney, liver, testis, thyroid and lung amongst 
others (NIH, 2020), the tissue expression of ACE2 is augmented in patients with type 1 
or type 2 diabetes, hypertension, and those who are under treatment with 
thiazolidinediones and ibuprofen (Fang, Karakiulakis, & Roth, 2020) however those who 
have not yet received treatment show lower expression levels, this mechanism is thought 
to be mediated by angiotensin II via ERK/p38 MAP or ERK1/2 and JNK, furthermore, 
should we block AT1R,  ACE2 levels rise, this rise can also be obtained by administering 
low doses of aldosterone, and decreases are seen when treated with endothelin 1 (Clarke 
& Turner, 2011); as well interethnic differences in expression patterns have been noted 
which may predispose to different susceptibilities (Cao, et al., 2020). One of the catalysed 
products of ACE2 is angiotensin (1-7) which serves to activate MAS1 proto-oncogene, 
which is a G protein-coupled receptor, its actions include: vasodilation, vascular 
protection, anti-fibrotic, anti-proliferative and reduction in pro-inflammatory cytokines 
(Clarke & Turner, 2011). Thus, we may consider ACE2 production pathways-blockage 
in order to diminish the probability of COVID19-virus to be received and internalized by 
the cell, by means of JNK (MAPK8), MAPK14 (p38), endothelin-1, AT1R agonists or 
aldosterone receptors antagonists (spironolactone, eplerenone). ACE2 has been shown to 
interact itself with two small molecules: moexipril and lisinopril, which may induce 
conformational changes in ACE2 necessary to diminish the hydrophobicity of the region 
responsible of the interaction with the spike (S) proteins of coronaviruses (TyersLab, 
2020), other chemicals have been noted: 2-amino-N,N-diethyl-1,3-benzothiazole-6-
carboxamide (also displaying anti-HIV reverse transcriptase activity and antibacterial 
activity against Mycobacterium tuberculosis) (PubChem, 2020), losartan, D-glucose, 
streptozotocin, captopril, diminazene aceturate (PubChem, 2020).  
BCLXL (BCL2 like 1).  
It belongs to the BCL2 protein family, which may homo- or heterodimerize and may 
either promote or suppress apoptosis regulators; this protein may locate at the outer 
mitochondrial membrane and may regulate the opining of the outer mitochondrial 
membrane channel thus being able to change mitochondrial membrane potential, reactive 
oxygen species production and release of cytochrome c, inducers of apoptosis. It shows 
two isoforms, the longer is antiapoptotic and the shorter is a proapoptotic (NIH, 2020), 
and it has been seen that BCLXL interacts with the envelope E protein of coronaviruses, 
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enabling then the apoptosis of T cells, compatible with the clinical features of 
lymphopoenia seen in coronaviruses infections (Yang, et al., 2005).  
Pathophysiology.  
Until now, we have unravelled two clues which may lead to the development of a solid 
pathophysiological theory: promotion of inflammasome formation and increase in the 
unfolded protein response, as well as changes in the apoptotic range of certain cells (such 
as T cells), in regards to the promotion of inflammasome formation, should there be an 
activation of the NLRP1 inflammasome by means of NLRP1’s cleavage, inducing 
NLPR1B, the latter would induce ASC protein or PYCARD protein (PYD and CARD 
domain containing protein), promoting the activation of caspase 1 and the consequent 
activation of interleukin 1 B and interleukin 18 or a pyroptotic death (Broz & Dixit, 2016). 
However it has been seen that the E protein from SARS viruses induce NLRP3 
inflammasome response (Chen, Moriyama, Chang, & Ichinohe, 2019) perhaps by means 
of the interaction there is sustained with BCLXL and pore formation in mitochondria, 
which may induce a potassium efflux (reducing the amounts of intracellular potassium) 
leading to NLRP3 activation, this aided by means of NEK7 which has been shown as a 
driving factor in cellular division, where NEK7 increased levels diminish mitotic rate and 
inflammasome activation and caspase 1 activation, also leading then to IL1B and IL18 
concentration increases (Broz & Dixit, 2016), the NLRP3 inflammasome activation has 
been related not only to recruitment of caspase 1 but also of caspase 4 and 5 (PubChem, 
2020), moreover, NLRP3 is an upstream activator of NFKB (NIH, 2020); because of 
these various interactions that NLRP3 shows and the possible clinical signs and 
symptoms we may encounter due to this activation, it could be advisable in certain cases 
to induce NLRP3 inactivation in order to diminish respiratory distress by means of small 
molecules (PubChem, 2020). In regards to IL1B signalling, it has been seen that it 
interacts with its receptor IL1R, activating IRAK4 (interleukin 1 receptor associated 
kinase), activating TRAF6 (TNF receptor associated factor 6) and some other 
downstream proteins (TAB2, TAK1, MKK3, p38), finally promoting the activation of 
IL6, IL8, as well as COX2, NFKB (Weber, Wasiliew, & Kracht, 2010); thus we may see 
as well that the restrictions in oxygenation seen in SARS may be very well induced by 
means of an overt inflammation by COVID19-virus. In turn, the unfolded protein 
response pathway that is seen activated by means of the envelope protein promotes the 
activation of NFKB and MAPK8, XBP1u (unspliced X box-binding protein 1) which 
promotes UPR target genes transcription, EIF2A (this factor inhibits translation and 
activates ATF4, augmenting UPR target genes transcription), AT6F (also promotes UPR 
target genes); the phenotype of the UPR target genes transcription is: autophagy, 
apoptosis, co-translational degradation, protein secretion, lipid synthesis (Hetz, 2012).  
Model.  
This model consists of two portions: a discrete time discrete Markov chain which shall 
predict the probability distribution of COVID19 in time in the Mexican population, for 
said chain we require the knowledge or the estimation of the infected population in given 
time, information that shall be known by the SIR (susceptible, infected, recovered) 
differential equation model of infections.   
Discrete Markov chain.  
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This chain consists of 32 states which correspond to the states in the political territory 
division of the Mexican Republic, thus 𝐸 = {𝑒𝑖: 𝑒 ∈ 𝑀, 𝑖 ∈ ℕ} where M stands for the 
Mexican territory, this set maps to 𝑆 = {𝑠1, 𝑠2, … , 𝑠32} of discrete states 𝑓: 𝐸 → 𝑆 in a 
bijective fashion; let us call U this process, then 𝑇 ⊂ 𝑈 where T stands for the set of 
temporal parameters, 𝑇 = {𝑡𝑗|𝑗 ∈ ℕ} where the j-th stands for the j-th day or [𝑗] = [𝑑𝑎𝑦], 
i.e., the corresponding unit of the temporal parameter is the day. Now let us establish the 
conditions of probability, ∀𝑠𝑖𝑅𝑠𝑘∃𝑝𝑖𝑘 ∈ Ω, for every existence of a relationship between 
the i-th and the k-th state there exists an associated probability ik for the transition from 
the i-th towards the k-th state, being this probability balanced between all the existent 
possible interactions between one i-th state and another any k-th state, for example, should 
the i-th state interact with n different states, then the associated probability for every 𝑠𝑖𝑅𝑠𝑘 
is 𝑝𝑖𝑘 =
1
𝑛
. The existence of an interaction between one state and another one is stated by 
means of the sharing of territorial boundaries. This process is featured by a stochastic 
matrix P,  
𝑃 =
(
 
 
𝑝11 𝑝12 𝑝13 … 𝑝1𝑛
𝑝21 𝑝22 𝑝23 … 𝑝2𝑛
𝑝31
⋮
𝑝𝑛1
𝑝32
⋮
𝑝𝑛2
𝑝33
⋮
𝑝𝑛3
…
⋱
…
𝑝3𝑛
⋮
𝑝𝑛𝑛)
 
 
 
This matrix is shown in Fig. 1 where ∑ 𝑝1𝑛
32
𝑖=1 = 1.  
The initial vector of this process is one which displays the COVID19 features in Mexico 
by means of the report corresponding to 11/03/2020 issued by the Mexican Health 
Department, with the following cases: Mexico City, 5 cases; Coahuila, 1 case; Chiapas, 
1 case; Sinaloa, 1 case (also a recovered case); Mexico State, 2 cases; Querétaro, 1 case. 
Thus, the total amount of cases can be described as the cardinality of the set of cases C, 
|𝐶| = 11 and the probabilities of the initial vector 𝜋0 for any given state are 𝜋𝑖 =
#𝑐𝑎𝑠𝑒𝑠
|𝐶|
. 
The vectors then can be determined for any given discrete time 𝑡𝑖 ∈ 𝑇, 
𝜋0 = 𝜋0 
𝜋1 = 𝜋0𝑃1 
𝜋2 = 𝜋0𝑃2 
⋮ 
𝜋𝑛 = 𝜋0𝑃𝑛 
 By computing the powers of the stochastic matrix we have computed the probability 
distributions when, 𝑛 = 2, 4, 8, 20, 40, 80, 160, 320 reminding us that the units of this 
temporal parameter is [𝑡] = [𝑑𝑎𝑦] thus we may compute the probability distributions of 
COVID19 for the following dates: 13/03/2020, 15/03/2020, 19/03/2020, 27/03/2020, 
31/03/2020, 20/04/2020, 30/05/2020, 18/08/2020, 25/01/2020 whose graph is shown in 
Fig. 2.  
When we compute the n-th power of the stochastic matrix we may realize as well of the 
stationary distribution of our set of variables or states, in this case, we may realize that 
there exists a tendency towards a stationary distribution, and the comparison between 
25/01/2021 and 11/03/2020 is shown in Fig. 3, in which we may come to notice the 
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decrease in inflexion points when 𝑛 = 320 and the tendency towards a stabilisation, 
where the peaks of infection are reduced, and a homogeneous spread of the disease is 
witnessed. The probability distribution of every state when 𝑛 = 320 is shown in Fig. 4; 
this last graph allows us to regard that the state with the highest probability or the highest 
prevalence at the given time is Campeche, followed by Quintana Roo; being the state with 
the lowest prevalence the Baja California Sur; but in no state do we observe 𝑝 = 0. We 
have then successfully computed the probability distribution of every state in time, 
however we do not know the precise population in given time, the precise amount of total 
infected people, for which we will need the second model.  
Modified SIR model.  
This model allows us to know the amount of susceptible, infected and recovered people 
in our population set. The model will be derived from the following thesis, 
𝑆 →𝑘1 𝐼 →𝑘2 𝑅 
Where S stands for susceptible population, I for infected population and R for recovered 
population; by means of chemical kinetics we may construct an analogy to these set of 
reactions, 
−
𝑑𝑆
𝑑𝑡
= 𝑘1𝑆 
Now, let us consider 𝑠0 as the initial susceptible population and 𝑠0 − 𝑥 as the amount of 
susceptible people lost in the time of the disease, 
𝑆 = 𝑠0 − 𝑥 
And we may say, 
−
𝑑𝑆
𝑑𝑡
= −
𝑑(𝑠0 − 𝑥)
𝑑𝑡
 
=
𝑑𝑥
𝑑𝑡
 
The corresponding differential equation is, 
𝑑𝑥
𝑑𝑡
= 𝑘1(𝑠0 − 𝑥) 
𝑑𝑥
𝑠0 − 𝑥
= 𝑘1𝑑𝑡 
Let us integrate this last expression, 
∫
1
𝑠0 − 𝑥
𝑑𝑥 = 𝑘1∫𝑑𝑡 
→ ln
1
𝑠0 − 𝑥
= 𝑘1𝑡 
→ [ln
1
𝑠0 − 𝑥
]
0
𝑥
= 𝑘1[𝑡]0
𝑡  
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→ ln
𝑠0
𝑠0 − 𝑥
= 𝑘1𝑡 
We obtain the following pieces of information, 
𝑥 = 𝑠0(1 − 𝑒
−𝑘1𝑡) 
𝑆 = 𝑠0 − 𝑥 
= 𝑠0𝑒
−𝑘1𝑡 
In order to compute the amount of infected people, we may define the equalities, 
𝐼 = 𝑥 − 𝑦 
𝑅 = 𝑦 
Then, 
𝑑𝑦
𝑑𝑡
= 𝑘2(𝑥 − 𝑦) 
= 𝑘2(𝑠0(1 − 𝑒
−𝑘1𝑡) − 𝑦) 
Which is a non-homogeneous linear differential equation, 
𝑑𝑦
𝑑𝑡
+ 𝑘2𝑦 = 𝑘2𝑠0(1 − 𝑒
−𝑘1𝑡) 
We may introduce the integrating factor, 
𝑑
𝑑𝑡
[𝑒𝑘2𝑡𝑦] = 𝑘2𝑠0(1 − 𝑒
−𝑘1𝑡)𝑒𝑘2𝑡 
We integrate, 
𝑒(𝑘2𝑡)𝑦 = 𝑘2𝑠0 [∫𝑒
𝑘2𝑡𝑦𝑑𝑡 − ∫𝑒𝑡(𝑘2−𝑘1)𝑑𝑡] 
→ 𝑒𝑘2𝑡𝑦 = 𝑘2𝑠0 [
1
𝑘2
𝑒𝑘2𝑡 −
1
𝑘2 − 𝑘1
𝑒𝑡(𝑘2−𝑘1)] 
By substituting limits, 
[𝑦]0
𝑦 = [𝑠0 −
𝑘2𝑠0
𝑘2 − 𝑘1
𝑒−𝑘1𝑡 + 𝑒−𝑘2𝑡]
0
𝑡
 
→ 𝑦 = 𝑒−𝑘2𝑡 −
𝑘2𝑠0
𝑘2 − 𝑘1
𝑒−𝑘1𝑡 +
𝑘2𝑠0
𝑘2 − 𝑘1
− 1 
Remembering, 
𝐼 = 𝑥 − 𝑦 
= 𝑠0 + 𝑒
−𝑘1𝑡 (
𝑘2𝑠0
𝑘2 − 𝑘1
− 𝑠0) − 𝑒
−𝑘2𝑡 −
𝑘2𝑠0
𝑘2 − 𝑘1
+ 1 
When we consider the initial susceptible population as, 
𝑠0 = 146.54𝑥10
6 
And the constants to be, 
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𝑘1 =
11
𝑠0
 
= 7.506𝑥10−8 
𝑘2 =
1
11
 
We may estimate the proportions of the infected, susceptible and recovered populations 
in Mexico (Table 1).  
Gather round! 
Let us now commute both models we have previously discussed in order to provide the 
cases’ distribution in the states of our Markov chain (or the States of Mexico) (Fig. 5) 
where we may notice the slow infective rate of COVID19, and a tendency to spread in 
every state in Mexico where by n=320, there will be 𝑐 ≥ 1 cases per state, should there 
be no preventive measures taken.  
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Addenda.  
 
Fig. 1. Graph showing the stochastic matrix corresponding to the transition probabilities between states.  
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 Fig. 2. Graph showing the probability distribution of COVID19 in a temporal perspective until 25/01/2021.  
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 Fig. 3. Graph comparing the probability distribution of COVID19 in Mexican population between 11/03/2020 and the last measurement made when 𝑛 = 320 or 
21/01/2021.  
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 Fig. 4. Probability distribution of every state when n=320.  
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Cases pb (15/03/2020) 43.8620184 146539956 0.1351439 
Cases pb (19/03/2020) 87.6310877 146539912 0.36322509 
Cases pb (27/03/2020) 109.489992 146539890 0.50289033 
Cases pb (31/03/2020) 218.623361 146539780 1.36232062 
Cases pb (20/04/2020) 436.544687 146539560 3.42634798 
Cases pb (30/05/2020) 872.141055 146539120 7.79969422 
Cases pb (18/08/2020) 1743.27722 146538240 16.5990005 
Cases pb (25/01/2021) 3485.5343 146536480 34.197 
Table 1. Number of estimated cases: infected (I), susceptible (S), recovered (R) people throughout time (Cases pb=probable cases).  
 
 
 
 
 
 
 
 
 
 
 
 
 Fig. 5. Graph displaying the distribution of estimated cases computed through the SIR model and the probabilities’ distribution by means of the Markov chain.  
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